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Direct amphotericin B-mediated tubular toxicity: Assessments of se-
lected cytoprotective agents. Amphotericin B (AB) may induce acute
renal failure by vasoconstrictive and tubulo-toxic effects. Although
mannitol, Ca2t channel blockers, and lipid-based AB preparations have
been suggested to mitigate in vivo AB nephrotoxicity, whether they
confer direct tubular cytoprotection has not been defined. Therefore,
this study assessed the impact of mannitol, verapamil/extracellular
Ca2t. and cholesteryl sulfate (CS) AB binding on AB cytotoxicity,
employing an isolated rat proximal tubular segment (PTS) preparation.
Alter 30 to 60 minutes of incubation, 0.2 mg/mI of AB (Fungizone)
caused marked toxicity, as assessed by LDH release (29 to 44%) and
ATP depletion (>90%). Approximately 40% of the LDH release could
be attributed to deoxycholate, the standard AB (Fungizone) solubilizing
agent. Both 100 mM mannitol and 100 m glucose decreased AB-
mediated LDH release, despite having a quantitatively trivial impact on
ATP concentrations (increments of s 1% at normal values). Dimeth-
ylthiourea (25 mM; equipotent to 100 msi mannitol/glucose as a hy-
droxyl radical scavenger) did not decrease LDH release. Neither
verapamil addition (100 jiM) nor Ca2 removal from the PTS buffer had
a protective effect. CS binding completely eliminated AB's toxicity (no
LDH or ATP losses). The effect of AB and CS-AB on concomitant 02
deprivation/reoxygenation (30 minuS mm) PTS injury was also as-
sessed. AB and hypoxia/reoxygenation caused additive, not synergis-
tic, LDH release whereas CS-AB had no adverse effect. We conclude
that: (I) AB (Fungizone) is directly toxic to PTS, due, in pan, to an
independent deoxycholate effect; (2) mannitol blunts AB cytotoxicity,
presumably via an osmotic, not anti-oxidant or ATP enhancing effect;
(3) extracellular Ca2t does not mediate AB PTS toxicity and thus,
verapamil confers no protection; (4) AB and 02 deprivation cause
additive, not synergistic, PTS injury; and (5) CS binding completely
blocks AB's direct tubulo-toxic effects.
Over the past 25 years, amphotericin B (AB) has been the
mainstay for treatment of most life-threatening fungal infections
[1, 2]. However, dose dependent nephrotoxicity has been a
persistent problem, often limiting its administration in full
therapeutic dosages [1—5]. AB nephrotoxicity is generally be-
lieved to involve both vascular and direct tubular cell mecha-
nisms [6—11]. Following its administration, an acute decrease in
renal blood flow can occur, possibly due to direct vasoconstric-
tive actions [12] and/or to alterations in tubuloglomerular feed-
back [13]. AB can also insert itself into cell membranes,
creating pores [14], thereby inducing direct proximal and distal
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tubular cytotoxicity [5, 6, 8]. Since renal hypoperfusion and
nephrotoxins often induce synergistic tubular damage [15], it is
possible that both these vascular and direct cytotoxic actions
are operative in AB-induced tubular cell necrosis.
Given the above pathophysiologic considerations, mannitol
and calcium channel blockers have each been suggested as
prophylactic interventions for AB-induced ARE [16—18] since
each may induce renal vasodilatation [19, 20] and confer direct
tubular cytoprotective effects [20, 21]. An alternative approach
for mitigating AB nephrotoxicity has been to incorporate the
drug into liposomes or to complex it with cholesteryl sulfate
[22—26]. By binding AB to lipid, the drug's insertion into cell
membranes may be decreased, possibly mitigating its toxicity
[22]. This approach also allows for the elimination of deoxy-
cholate, a bile salt, as the traditional AB-solubilizing agent.
Since bile salts can exert a detergent action on cell membranes,
it is possible that AB nephrotoxicity, as observed with the
standard AB preparation (Fungizone; Squibb Pharmaceuticals,
Princeton, New Jersey, USA), could be due to both AB and bile
salt effects.
Selected in vivo investigations employing mannitol [16, 17],
Ca2 channel blockers [18], and lipid based AB preparations
[24, 27] have suggested significant reductions in nephrotoxicity,
as gauged by whole kidney functional criteria. However, in vivo
studies do not permit a ready dissociation of vascular versus
direct cytoprotective effects. Thus, the present study was
conducted with the following goals in mind: (1) to discern
whether mannitol, calcium channel blocker therapy, and AB-
lipid binding can, in fact, confer direc( proximal tubular cyto-
protection against AB cytotoxicity; (2) to determine the relative
efficacies of each of these prophylactic approaches; (3) to assess
whether deoxycholate has an independent proximal tubular
cytotoxic action; and (4) to determine whether AB and 02
deprivation/reoxygenation induce synergistic proximal tubular
cell injury. If so, does AB-lipid binding prevent this interaction?
Methods
Proximal tubular segment (PTS) preparations
PTS were isolated from male Sprague-Dawley rats (200 to 250
g; Harlan Sprague Dawley, Indianapolis, Indiana, USA) by a
previously described technique [28]. In brief, rat kidneys (from
I or 2 rats per experiment) were rendered near bloodless by in
vivo perfusion with a balanced salt solution [28], the kidneys
were resected, and the cortices were finely minced with a razor
blade. The minced tissues were digested for 40 minutes in a
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collagenase containing buffer [28] to which deferoxamine was
added (0.66 mg/mI; to chelate free Fe). Following digestion, the
pelleted tissues were washed five times to remove the collage-
nase and deferoxamine. Finally, viable PTS were isolated from
the preparation by centrifugation through 31% Percoll [28]. The
pelleted PTS were suspended to a concentration of 2 to 4 mg
PTS protein/mi in a nutrient buffer consisting of: NaCI 100 mM,
KC1 2.1 mi, NaHCO3 25 mri, KH2PO4 2.4 mrst, CaCI2 1.2 mM,
MgC12 1.2 mrt, MgSO4 1.2 m, glucose 5 m, Na lactate 4 mM,
Na butyrate 10 msi, alanine 1 mri, dextran T40 0.6%; gassed
with 95% 02/5% C02; final pH 7.4. The PTS were re-warmed
from 4°C (isolation temperature) to 36°C over 15 minutes, a 150
l aliquot was used to determine the baseline percentage of
LDH released (as an index of PTS viability [21, 28—30]), and
then each sample was split into 3 to 6 equal aliquots, depending
on the nature of the protocol, as described below. All protocols
were performed under oxygenated (95% O/5% C02) conditions
at 36°C in a shaking water bath, if not otherwise stated.
AB-induced PTS cytotoxicity: Mannitol effects
In pilot studies, it was observed that the lowest dose of AB to
induce a significant increase in LDH release during a 60 minute
incubation was 0.1 mg/mI, whereas 0.2 mglml of AB induced
substantial cytotoxicity, as assessed by LDH release (Results).
Thus, the 0.2 mg/mi dose was used as the challenge for
assessing mannitol's protective effects. Five PTS preparations
were used for these experiments, each one being divided into
three equal aliquots and treated as follows: (1) AB addition
(Fungizone); (2) AB addition + 100 mrvi mannitol; and (3) no
addition (controls). After 60 minutes of incubation, the percent-
age of LDH released was assessed.
To determine whether mannitol confers protection against
AB toxicity by its action as a hydroxyl radical (OH) scavenger
[30], a second set of experiments was performed. Four PTS
preparations were divided into the following aliquots: (1) AB
alone, 0.2 mg/mi; (2) AB + 100 mri mannitol; (3) AB + 25 mM
dimethylthiourea (DMTU; equivalent to 100 mrs mannitol as a
.OH scavenger) [30]; (4) AB + 25 mi mannitol as an osmotic
control for DMTU; and (5) no additions. To assess whether
another osmotically active agent could reproduce mannitol's
cytoprotective effect, a sixth aliquot from each of the above
PTS preparations was incubated with AB + 100 m glucose.
After 60 minutes, the percent of LDH released from each
aliquot was determined.
Verapamil and extracellular Ca2 effects on AB cytotoxicity
To assess the influence of extraceilular Ca2 and calcium
channel blocker therapy on AB-induced PTS toxicity, five PTS
preparations were each divided into six aliquots: (1) incubation
with AB, 0.2 mg/ml; (2) incubation with AB + 100 /LM vera-
pamil [21]; and (3) AB incubation in PTS buffer devoid of Ca2
(normally 1.2 mM). The remaining three PTS aliquots served as
controls for the above, being incubated with: (1) no addition; (2)
PTS buffer devoid of both Ca2 and AB; and (3) verapamil
incubation, 100/SM, in the absence of AB. After 60 minutes, the
percent of LDH released was assessed.
AB, cholesteryl-sulfate complexed AB, and deoxycholate PTS
toxicity
In these experiments, PTS cytotoxicity of the traditional
miceilar AB (Fungizone) preparation was contrasted with that
of deoxycholate alone and of cholesteryl sulfate-compiexed AB
(CS-AB) (AB colloidal dispersion, Liposome Technologies
Inc., Menlo Park, California, USA). The CS-AB preparation is
a stable AB colloidal dispersion made from cholesteryl sulfate
and AB in a 1: 1 molar ratio, forming discoidal lipid-AB com-
plexes of -100 nm in diameter [22, 23]. Five PTS preparations
were used for these experiments, each one being divided into
four aliquots: (1) incubation without any addition (controls); (2)
incubation with 0.2 mg/ml of AB (Fungizone); (3) incubation
with 0.16 mg/ml of sodium deoxycholate (the amount present in
the above Fungizone treated aliquot; pH maintained at 7.4); and
(4) incubation with 0.2 mg/mi of AB, as the CS-AB formulation.
After completing 60 minutes of incubation, the percent of LDH
released was determined for each aiiquot.
To further assess the relative safety of CS-AB, five PTS
aliquots, each obtained from a different PTS preparation, were
incubated for 60 minutes with 0.6 mg/ml of AB as the CS-AB
formulation (3 times the dose used in the above experiments).
After 60 minutes, the percent of LDH released was assessed
and it was contrasted to that seen in co-incubated control PTS
aliquots (that is, no drug addition).
Assessments of AB cytotoxicity after 30 minutes of incubation
In each of the above experiments, AB toxicity was assessed
at only one time point, 60 minutes. To help validate those
results, AB-induced PTS injury was assessed at a different time
point, 30 minutes. Five PTS preparations were each divided
into six aliquots: (1) no addition (buffer only); (2) AB addition,
0.2 mglml; (3) CS-AB, 0.2 mg/mi; (4) AB + 100 mri mannitol;
(5) AB + 100 mi glucose; and (6) AB + 100 /LM verapamil.
After 30 minutes, the percent LDH released was determined.
As an additional marker of cell injury, PTS ATP concentrations
were measured by high performance liquid chromatography
(HPLC), as previously described [28], the results being ex-
pressed as nmoies/mg PTS protein.
Hypoxic/re-oxygenation PTS injury: Effect on concomitant
AB and CS-AR exposure
To ascertain whether AB or CS-AB and 02 deprivation/re-
oxygenation cause synergistic PTS injury, five PTS prepara-
tions were each divided into six aliquots: (1) AB addition, 0.1
mg/mi, with continuous oxygenation x 45 minutes; (2) CS-AB
addition, 0.1 mg/ml, with continuous oxygenation x 45 min-
utes; (3) no addition, with continuous oxygenation X 45 min-
utes; (4) AB addition, 0.1 mg/mi, followed immediately by 30
minutes of hypoxic (95% N2/5% C02) and then 15 minutes of
re-oxygenation incubation [28]; (5) CS-AB addition, 0.1 mg/mi,
followed immediately by 30 minutes of hypoxic and then 15
minutes of reoxygenation incubation; and (6) no addition, the
PTS being subjected only to 30 minutes of hypoxia and 15
minutes of reoxygenation. At the end of each protocol (45 mm),
the percent of LDH released was determined.
AR dose-response relationships
The following experiment assessed the relationship between
AB dosage, PTS ATP concentrations, and LDH release. Four
PTS preparations were each divided into seven aliquots: AB
addition; (1)0.2mg/mi, (2) 0.1 mg/mi, (3)50 /Sg/ml, (4)25 /Sg/mi,
(5) 12.5 /Sg/ml, or (6) 6.25 /Sg/ml; or (7) buffer addition. After a
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one hour incubation, the percent LDH released and PTS ATP
concentrations were determined.
Calculations and statistics
All values represent means 1 SEM. The percent of LDH
released after completing each experimental protocol is given as
the absolute percent of LDH released by the end of the
experiment minus the baseline percent of LDH released (that is,
the amount released during the 15 mm rewarming process).
Thus, the corrected value represents the percent of LDH which
was released in response to each experimental incubation. For
each set of experiments, the results were first analyzed for
statistical differences by multivariate analysis of variance,
unless stated otherwise. The paired Student's t-test with Bon-
ferroni correction was used as an aftertest for assessing statis-
tical differences between two specific treatments (data report-
ed). To confirm these aftertest results, a Newman Keuls test




The percent of LDH released after the 15-minute PTS re-
warming process ranged from 7.1% to 12.3% (mean 9.1
0.2%). The viability of the preparations over time was indicated
by the control PTS releasing only 3 0.4% and 4.7 0.4%
LDH over the 30 minute and the 45 to 60 minute incubation
periods, respectively.
Mannitol effects on AB-induced PTS toxicity during 60 mm
incubarions
AB, 0.2 mg/mI, caused 35 4% LDH release (Fig. lA).
Addition of 100 ma'i mannitol conferred significant cytoprotec-
tion, decreasing LDH release to 21 2% (P < 0.005; Fig. IA).
25 mri DMTU, equivalent to 100 mtvt mannitol as a .OH
scavenger 130], had no protective influence (Fig. lB). Reducing
the mannitol concentration from 100 m to 25 m eliminated its
cytoprotective effect (Fig. 1B). One hundred millimolar glucose
Fig. 1. Percent of LDH released during 60
minutes of incubation (that is, above basal
values) with buffer alone (controls),
amphotericin B (AB; Fungizone, 0.2 mg/mI),
or AB + 100 msc mannitol. LOll release for
each of these three treatment groups differed
from each other; P < 0.005). B. PTS were
incubated for 60 minutes with buffer alone
(controls, AB (0.2 mg/mI), or AB + 25 mM
DMTU, 25 m, or 100 mM mannitol (man), or
100 m glucose (glu). DMTU and 25 mM
mannitol conferred no protection but 100 mas
mannitol and glucose significantly decreased
LDH release, compared to AB alone. The 100
m glucose was more protective than 100 mri
mannitol (P < 0.01).
addition induced slightly, but significantly (P < 0.01), greater
cytoprotection than did 100 mr's mannitol (Fig. 1B).
Ca2 and verapamil effects on AB PTS toxicity during 60
minutes of incubation
Incubation of non-AB exposed PTS in the presence or
absence of extracellular Ca did not influence their viability,
as assessed by LDH release (4 0.5%; both groups) (Fig. 2).
However, verapamil addition slightly, but significantly, in-
creased LDH release (from 4 to 6%; P = 0.001, compared to
Ca2 exposed PTS), suggesting a slight cytotoxic effect (Fig.
2B). The presence or absence of extracellular Ca2 did not
significantly influence AB cytotoxicity (30 vs. 33%, respec-
tively; NS). However, verapamil paradoxically increased AB-
induced LDH release from 30 to 41% (P < 0.015, compared to
Ca2/AB exposed PTS aliquots; Fig. 2B).
AB, CS-AB, and deoxycholate cytotoxicity during 60 minute
incubations
The AB (0.2 mg/mI) treated PTS developed 33 1% LDH
release (P < 0.0025 vs. controls; Fig. 3). Deoxycholate, in the
absence of AB, caused 15 2% LDH release (P < 0.005
compared to controls). Thus, approximately half of the AB
(Fungizone) toxicity could be attributed to an independent
deoxycholate effect. In contrast, PTS incubation with either 0.2
or 0.6 mg/mI of AB, as the CS-AB formulation, caused no LDH
release, compared to co-incubated control PTS.
Assessments of AB toxicity after 30 minutes of incubation
As shown in Figure 4, after a 30 minute incubation, 0.2 mg/nil
AB caused significant cytotoxicity, increasing LDH release to
29 3% and decreasing ATP concentrations by 93%. Both
mannitol and glucose conferred significant cytoprotection, as
assessed by a decrease in LDH release (confirming the 60 mm
incubation results). Glucose, was, once again, slightly more
protective than mannitol (14 1% vs. 18 2%; P < 0.05).
Despite this cytoprotection, neither mannitol nor glucose had a
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Control AB DOC CS-AB CS-AB
0.2 mg/mi 0.2 mg/mi 0.6 mg/mI
Fig. 3. A 60 minute incubation with buffer alone (controls), AB, 0.2
mg/mi, deoxycholate (DOG), or CS-AB, 0.2 or 0.6 mg/mi. The CS-AB
caused no increase in LDH release, compared to controls. Approxi-
mately one half of the AB (Fungizone) toxicity could be directly
attributed to an independent deoxycholate effect.
(AB alone 0.71 0.04; AB + mannitol 0.75 0.05; AB +
glucose 0.84 0.05 nmol/mg protein). Although the latter was
statistically higher than the former two (P <0.05), the increase
was <1% of normal ATP concentrations. Verapamil did not
decrease either LDH release or the degree of ATP depletion
(Fig. 4).
Hypoxic/re-oxygenation experiments
The 0.1 mg/ml AB dosage caused a slight, but significant
increase in LDH release, independent of superimposed hy-
poxic-re-oxygenation injury (4% increment over control incu-
bated PTS; P < 0.001; Fig. 5A). The 0.1 mg/mi AB dosage,
given as the CS-AB formulation, caused no LDH release,
compared to co-incubated controls. When the hypoxia-re-
oxygenation protocol was conducted in the presence of CS-AB,
no increased injury resulted. AB (0.1 mg/ml Fungizone) +
hypoxia/re-oxygenation caused a greater percent LDH release
than did hypoxia/re-oxygenation alone (by 7%; P < 0.01) (Fig.
Fig. 2. A. A 60 minute incubation of PTS
with Ca2 containing buffer, non-Ca2
containing buffer, and with Ca2 containing
buffer plus verapamil (verap), all in the
absence of AB. Ca2 vs. no Ca2 incubation
had no effect on LDH release. However,
verapamil slightly, but significantly, increased
LDH release (from 4 to 6%; P = 0.001). B.
The above experiment was repeated in the
presence of AB, 0.2 mg/ml. Ca2 and non
Ca2 containing buffers produced the same
results whereas verapamil + Ca2 caused
greater LDH release than Ca2 incubation
alone (P < 0.015).
SB). However, when the latter result was corrected by subtract-
ing out the independent AB effect (4%), these two groups no
longer significantly differed (indicating a lack of synergistic
injury).
AB dose-response curve
Only the 0.2 mg/ml and 0.1 mg/ml AB dosages significantly
increased LDH release (44 5%; 9 1% respectively) com-
pared to the controls (5 1%; P < 0.05). However, a striking
inverse relationship between the AB and ATP concentrations
was observed over the entire range of the titration curve (AB
dosages 200, 100, 50, 25, 12.5, 6.25, 0 g/ml: ATP: 0.5 0.04;
3.1 0.6; 7.0 0.04; 7.9 0.4; 8.2 0.4; 8.2 0.3; 8.6 0.3
nmollmg protein; r = —0.96; the last two ATP concentrations
being statistically different by paired Student's t-test, P < 0.05).
Discussion
In selected patient populations, AB remains a leading cause
of ARF. For example, in a recent study of patients undergoing
bone marrow transplantation, AB was implicated in 85% of
ARF cases [311. A similar association was noted in a clinical
series reported by Kone et al [32]. Because of this propensity to
induce ARF, effective prophylaxis for AB nephrotoxicity has
been sought. Mannitol, verapamil, and lipid-based AB prepara-
tions have each been suggested to confer renal functional
protection, as determined in whole animal experiments. In the
present study, we have attempted to define the efficacy of these
interventions for preventing AB-mediated proximal tubular
cytotoxicity.
Because of time constraints imposed by PTS viability ex
vivo, a dose of AB which causes substantial tubular cell killing
(as defined by LDH release) within 60 minutes was sought.
Slight cytotoxicity was observed with a 0.1 mg/mi concentra-
tion (-'-4 to 9% increment in LDH release), whereas with 0.2
mg/ml, 30 to 44% of LDH was released. Thus, to permit an


































was used in subsequent experiments. To define whether deoxy-
cholate, the traditional AB solubilizing agent, contributes to
this toxicity, an amount of deoxycholate equivalent to that
present in the 0.2 mg/ml AB dosage was incubated with PTS.
Fifteen percent LDH release was observed, indicating that
approximately 40% of the in vitro AB (Fungizone) toxicity
could be directly attributed to deoxycholate. An important, but
unanswered question, is whether this deoxycholate toxicity
sensitizes to AB's direct cytotoxic effect. If so, then it is
theoretically possible that replacing deoxycholate with a differ-
ent, nontoxic, solubilizing agent could substantially mitigate
Fungizone's adverse tubular effects.
Having defined an in vitro model for AB nephrotoxicity, and
deoxycholate's contribution to it, we next assessed mannitol's
Fig. 4. A. Percent of LDH released during 30
minutes of incubation with buffer alone
(controls); AB, 0.2 mg/mI; AB + 100 mss
glucose (glu); AB + 100 mM mannitol (man);
AB + 100 sM verapamil (verap); or with CS-
AB, 0.2 ,ng/ml. The CS-AB and control
________________
incubation results did not significantly differ.
Glucose and mannitol each conferred
significant protection, compared to AB alone,
and the degree of protection was significantly
greater with glucose (P < 0.05). In contrast,
_________________
verapamil had no effect. B. ATP
concentrations in the above PTS experiments.
AB induced >90% ATP depletion whether or
___________________
not cytoprotective agents were present.
However, the glucose treatment did slightly
increase ATP, compared to the AB and AB-
mannitol groups (P <0.05). In contrast, CS-
AB did not lower ATP, compared to the non-
AB exposed controls.
ability to confer cytoprotection, since this agent has been
suggested as prophylaxis for AB-induced ARF [16, 17]. Be-
cause AB creates membrane pores, permitting transcellular ion
and fluid fluxes [14], it was reasoned that an increase in
extracellular fluid osmolality could prevent cell swelling, and
thus, further membrane disruption and lethal cellular injury [20,
33]. Addition of 100 m mannitol to the PTS buffer appeared to
exert this effect since AB-induced LDH release was decreased
after both 30 and 60 minute incubations. However, this protec-
tive influence should be viewed as modest, since it was incom-
plete and because a more therapeutically relevant mannitol
concentration (25 mM) was without a beneficial impact. To
assess whether mannitol's protective influence might have been
mediated by its ability to scavenge hydroxyl radical (.OH), the
60-minute AB incubations were conducted with 25 mi DMTU,
equipotent to 100mM mannitol as a .OH scavenger [30]. That no
protection was discerned serves to dissociate mannitol's anti-
oxidant properties from the observed cytoprotective effect. To
help substantiate that mannitol's beneficial action was due to
increased buffer osmolality, AB challenged PTS were incubated
with 100 m glucose and even greater protection resulted.
Surprisingly, neither the mannitol nor glucose mediated cyto-
protection was associated with more than trivial ATP incre-
ments. Thus, these results strongly suggest that these agents
conferred protection not by improving cellular energetics, but
rather by mitigating a post-ATP depletion event (for example,
cell swelling). Why glucose was more protective than mannitol
remains unknown.
The next goal of this study was to assess the importance of
extracellular Ca2 on AB-induced PTS toxicity and to deter-
mine whether Ca2 channel blocker therapy confers protection.
Thus, PTS were exposed to AB in the presence or absence of
extracellular Ca2. Alternatively, PTS were incubated with
Ca2 in the presence of verapamil. Ca2 depletion from the PTS
buffer conferred no protection, indicating that extracellular
Ca2 was not a mediator of AB-induced cytotoxicity in this









































Controls AB CS-AB Controls AB CS-AB
Fig. 5. A. At a dose of 0.1 mg/mi, AB, but not CS-AB, caused slight
(4%) LDH release, compared to controls (P < 0.001) during continuous
oxygenated incubation (45 mm). B. AB addition to PTS increased the
percent of LDH released during 30 minutes of hypoxia-IS minutes of
re-oxygenation by 7%. However, when the independent AB effect,
depicted in A, was subtracted out, the percent of LDH released during
hypoxia-re-oxygenation no longer significantly differed from the
non-AB treated PTS. In contrast, CS-AB addition had no adverse effect
on 02 deprivation-re-oxygenation mediated LDH.
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channel blocker therapy had no beneficial effect. Rather, vera-
pamil appeared to somewhat worsen AB toxicity, increasing
LDH release from 30% to 41% after a 60 minute incubation. The
reason for this surprising result was not discerned. However,
that verapamil slightly, but significantly, increased LDH release
from PTS even in the absence of AB exposure (Fig. 2) suggests
that it can exert a slight cytotoxic effect.
In contrast to mannitol and verapamil, cholesteryl sulfate
(CS) binding of AB totally blocked its cytotoxicity. At a dose of
0.2 mg/ml, no increment in LDH release was noted after either
30 or 60 minutes. Furthermore, it did not decrease 30-minute
P1'S ATP concentrations, a highly sensitive marker of cell
injury (as shown by the AB dose-response curve). Increasing
the CS-AB dose threefold still failed to cause significant LDH
release, assessed after 60 minutes. Undoubtedly, this protec-
tion resulted from a reduction in AB's affinity for PTS mem-
branes, caused by the CS-AB bond. It is also likely that
elimination of deoxycholate contributed to this decreased AB
toxicity, relative to the traditional Fungizone formulation.
Since in vivo AB nephrotoxicity may result from both tubulo-
toxic and vasoconstrictive effects, we next assessed whether
AB or CS-AB, and 02 deprivation/re-oxygenation induced
synergistic PTS injury. To make this assessment, a minimally
toxic Fungizone concentration (0.1 mg/mI) was used: by so
doing, substantial, direct AB toxicity was avoided, increasing
the potential for detecting synergistic damage. Despite the fact
that this 0.1 mg!ml AB dose was slightly toxic (increasing LDH
release by --4%), no synergy with hypoxic/reoxygenation injury
was apparent, since the total LDH released approximated the
sum of the independent AB and 02 deprivation/re-oxygenation
effects. Therefore, it appears unlikely that Fungizone directly
predisposes tubular cells to superimposed 02 deprivation/re-
oxygenation injury. Of note, CS-AB had no influence whatso-
ever on the 02 deprivation/re-oxygenation injury protocol. This
result further suggests the potential safety of the CS-AB prep-
aration, at least at the tubular cell level.
In conclusion, the results of this study indicate that: (1) AB
induces direct, dose-dependent, PTS cytotoxicity; (2) approxi-
mately 40% of this toxicity can be explained by deoxycholate,
the AB solubilizing agent; (3) hypertonic mannitol mitigates
AB-PTS cytotoxicity, presumably by exerting an osmotic, not
an anti-oxidant, or ATP enhancing effect; (4) extracellular Ca2
is not required for AB to induce cytotoxicity, and, thus, Ca2
channel blocker therapy confers no protection; (5) AB and
hypoxialre-oxygenation induce additive, not synergistic, in
vitro PTS injury; and (6) binding of AB to cholesteryl sulfate
eliminates its cytotoxicity. Although each of these conclusions
has potential clinical relevance, a number of important, and
obvious, caveats must be borne in mind: (1) data from isolated
PTS experiments may not have direct relevance to the in vivo
kidney; (2) in vivo AB toxicity generally requires days or weeks
to develop, whereas, in these experiments, an acute insult was
induced; and (3) in order to induce this acute toxicity, a very
high AB dosage was used. However, it is noteworthy that AB
tissue concentrations comparable to those used in this study
have been observed following clinical AB therapy [34]. This
suggests that the Fl'S model may have some utility for studying
AB nephrotoxicity.
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